News
TVGNW
0.0695
+15.64%
0.0094
Tevogen Bio Regains Full Nasdaq Listing Compliance
TipRanks · 6h ago
Tevogen regains compliance with Nasdaq continued listing requirements
TipRanks · 6h ago
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Barchart · 11h ago
Weekly Report: what happened at TVGN last week (0921-0925)?
Weekly Report · 2d ago
Weekly Report: what happened at TVGN last week (0914-0918)?
Weekly Report · 09/21 10:22
Tevogen Bio grants major performance-based executive stock awards
TipRanks · 09/16 21:27
Weekly Report: what happened at TVGN last week (0907-0911)?
Weekly Report · 09/14 10:27
Tevogen Bio regains Nasdaq listing compliance status
TipRanks · 09/10 13:47
Weekly Report: what happened at TVGN last week (0831-0904)?
Weekly Report · 09/07 10:20
Weekly Report: what happened at TVGN last week (0824-0828)?
Weekly Report · 08/31 10:28
Tevogen Bio Shareholders Approve Governance-Enhancing Charter Changes
TipRanks · 08/26 19:27
Weekly Report: what happened at TVGN last week (0817-0821)?
Weekly Report · 08/24 10:29
Weekly Report: what happened at TVGN last week (0810-0814)?
Weekly Report · 08/17 10:30
Weekly Report: what happened at TVGN last week (0803-0807)?
Weekly Report · 08/10 10:24
Weekly Report: what happened at TVGN last week (0727-0731)?
Weekly Report · 08/03 10:24
Tevogen Bio Holdings Rebrands as Tevogen Inc.
TipRanks · 07/30 12:57
Tevogen Bio becomes Tevogen Inc.
Seeking Alpha · 07/29 13:12
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30
Benzinga · 07/29 12:03
*Tevogen Bio Holdings to Change Name to Tevogen
Dow Jones · 07/29 12:02
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
NASDAQ · 07/28 03:29
More
Webull provides a variety of real-time TVGNW stock news. You can receive the latest news about TEVOGEN INC through multiple platforms. This information may help you make smarter investment decisions.
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.